T0	Outcomes 1373 1407	MEASURES Progression-free survival
T1	Outcomes 1490 1552	including overall survival, response rate, and safety/toxicity
T2	Outcomes 1971 1981	P < .001).
T3	Outcomes 1982 2005	Median overall survival
T4	Outcomes 2279 2305	selumetinib achieved tumor